Key result
Doxorubicin therapy in dogs with cancer significantly increased serum cTnI levels at weeks 9 and 12 (p=0.027) compared to untreated dogs, preceding echocardiographic changes.
Why the study?
Does doxorubicin treatment increase cTnI levels and alter echocardiographic parameters in dogs with cancer?
Observational (n=12)
Does doxorubicin treatment increase cTnI levels and alter echocardiographic parameters in dogs with cancer?
Serum cTnI can serve as a sensitive marker for the early detection of doxorubicin-induced cardiotoxicity in dogs, increasing before structural echocardiographic changes occur.
Supports cTnI as early doxorubicin cardiotoxicity marker in dogs; leaves open human translation.
The study aimed to evaluate whether cardiac troponin I (cTnI) and pulsed-wave tissue Doppler imaging (TDI) measurements can detect cardiac changes during doxorubicin therapy in dogs with various types of cancers compared to conventional echocardiography. Serial measurements of cTnI and conventional and pulsed-wave TDI echocardiography were performed in 12 dogs diagnosed with various types of cancers at day 0, weeks 3, 6, 9, and 12 prior to each doxorubicin injection. After treatment with doxorubicin, dogs had significantly increased cTnI levels at week 9 (p = 0.027) and 12 (p = 0.027) compared to normal untreated dogs. Dogs had increased cTnI levels during doxorubicin therapy (p = 0.004). Percent left ventricular ejection fraction (LVEF) and fractional shortening (FS) assessed by 2-dimensional and M-mode echocardiography significantly decreased at weeks 9 and 12. Pulsed-wave TDI derived myocardial performance index (MPI) increased significantly at weeks 9 and 12 compared to day 0 (p = 0.028 and 0.040, respectively). In conclusion, dogs treated with doxorubicin had increased cTnI levels. An increase in cTnI levels was detected before echocardiographic value changes. Serum cTnI can be a sensitive marker for detection of cardiotoxicity in dogs treated with doxorubicin.
No takes yet. Share an insight, caveat, or question.
Surachetpong et al. (2016) conducted an observational in Various types of cancers (n=12). Doxorubicin therapy vs. Normal untreated dogs was evaluated on Cardiac troponin I (cTnI) levels (p=0.027). Doxorubicin therapy in dogs with cancer significantly increased serum cTnI levels at weeks 9 and 12 (p=0.027) compared to untreated dogs, preceding echocardiographic changes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: